Display options
Cite
Parums DV. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy. Med Sci Monit. 2021;27:e934625doi: 10.12659/MSM.934625.
Parums, D. V. (2021). Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy. Medical science monitor : international medical journal of experimental and clinical research, 27e934625. https://doi.org/10.12659/MSM.934625
Parums, Dinah V. "Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy." Medical science monitor : international medical journal of experimental and clinical research vol. 27 (2021): e934625. doi: https://doi.org/10.12659/MSM.934625
Parums DV. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy. Med Sci Monit. 2021 Sep 06;27:e934625. doi: 10.12659/MSM.934625. PMID: 34483336; PMCID: PMC8434768.
Copy Download .nbib Format: NLM
Share it on

Med Sci Monit. 2021 Sep 06;27:e934625. doi: 10.12659/MSM.934625.

Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy.

Medical science monitor : international medical journal of experimental and clinical research

Dinah V Parums

Affiliations

  1. Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA.

PMID: 34483336 PMCID: PMC8434768 DOI: 10.12659/MSM.934625

Abstract

In the past 18 months, accelerated vaccine development to prevent or reduce the severity of coronavirus disease 2019 (COVID-19) has resulted in rapid global emergency regulatory approvals, including the US Food and Drug Administration (FDA) emergency use authorization (EUA) approvals. On August 23, 2021, the US FDA gave the first full regulatory approval for a COVID-19 vaccine and approved the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) for individuals 16 years and older. In the US, there is a continued EUA for individuals aged 12-15 years of age. Also, the EUA includes the administration of a third or booster dose in immunocompromised individuals at increased risk for severe COVID-19. This Editorial aims to present an update on the first COVID-19 vaccine to receive full regulatory approval, the Pfizer-BioNTech vaccine, and the implications for real-world public health during the global COVID-19 pandemic and increasing concerns for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

References

  1. Eur J Epidemiol. 2020 Aug;35(8):775-779 - PubMed
  2. JAMA. 2021 Jun 22;325(24):2457-2465 - PubMed
  3. Discoveries (Craiova). 2021 Mar 5;9(1):e122 - PubMed
  4. Med Sci Monit. 2021 Jun 21;27:e933622 - PubMed
  5. Euro Surveill. 2021 Apr;26(17): - PubMed
  6. N Engl J Med. 2021 Mar 8;384(15):1466-1468 - PubMed
  7. Am J Health Syst Pharm. 2020 Dec 4;77(24):2112-2113 - PubMed
  8. Front Public Health. 2021 Apr 21;9:626852 - PubMed
  9. BMJ. 2021 May 13;373:n1088 - PubMed
  10. N Engl J Med. 2020 Dec 31;383(27):2603-2615 - PubMed
  11. Med Sci Monit. 2021 Jun 14;27:e933554 - PubMed
  12. JAMA. 2021 Aug 24;326(8):728-735 - PubMed
  13. N Engl J Med. 2021 Sep 16;385(12):1078-1090 - PubMed

Substances

MeSH terms

Publication Types